No Picture
Los Angeles Biotech Trending News

City of Hope names 5 new board members

DUARTE, Calif.–(BUSINESS WIRE)–City of Hope announced the appointment of five new members to the boards of directors of three entities within the City of Hope enterprise. Click to view original post

No Picture
Los Angeles Biotech Trending News

Dermavant Announces First Patient Dosed in ADORING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Atopic Dermatitis

LONG BEACH, Calif., & BASEL, Switzerland,–(BUSINESS WIRE)–Dermavant Announces First Patient Dosed in ADORING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Atopic Dermatitis Click to view original post

No Picture
Los Angeles Biotech Trending News

Rocket Lab Lands Multi-Launch Deal to Deploy Entire IoT Satellite Constellation for Kinéis

LONG BEACH, Calif.–(BUSINESS WIRE)—- $RKLB–Rocket Lab USA, Inc (“Rocket Lab” or the “Company”) (Nasdaq: RKLB), a leading launch provider and space systems company, today announced it has been awarded a contract to deploy an entire […]

No Picture
Los Angeles Biotech Trending News

Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

MARINA DEL REY, Calif.: MARINA DEL REY, Calif., Sept. 8, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat […]

No Picture
Los Angeles Biotech Trending News

As tezepelumab awaits FDA decision, Amgen and AstraZeneca tout more data from the Phase III study

As AstraZeneca and Amgen’s Dupixent challenger awaits a decision by the FDA, the companies are touting new data they hope could bolster their case. Researchers revealed additional results from a pivotal Phase III trial for […]

No Picture
Los Angeles Biotech Trending News

Amgen, AstraZeneca dig into data from phase 3 asthma trial, emerging with evidence of efficacy in hard-to-treat subgroup

Amgen, AstraZeneca dig into data from phase 3 asthma trial, emerging with evidence of efficacy in hard-to-treat subgroup ntaylor Tue, 09/07/2021 – 08:14 Click to view original post